Circadian Therapeutics was founded in September 2016 as a spin-out from Oxford University with the aim to deliver benefit and value for all its stakeholders; patients, healthcare providers and investors. The world-leading science generated by its academic founders is the foundation for the development of therapeutic products based on the understanding of the molecular control of circadian rhythms. With an experienced leadership team and a track-record of building operational capabilities and delivering shareholder value, the Company will develop therapeutics targeting serious diseases associated with circadian rhythm disruption.